Jan 13, 2020 / 04:00PM GMT
Robert Justin Marcus - JP Morgan Chase & Co, Research Division - Analyst
Good morning, everyone. Welcome to the JPMorgan Healthcare Conference. I'm Robbie Marcus, the med tech analyst.
I'm very happy to have DexCom here to kick off the medical device track here at the conference. Proud to introduce Kevin Sayer, President, Chairman and CEO of DexCom.
Kevin R. Sayer - DexCom, Inc. - Executive Chairman, CEO & President
Thank you very much, Robbie. It's a pleasure to be here today. Actually, I think this is the fifth time I've been here as the CEO of DexCom to make this presentation. I'm pretty excited to start the presentation off the same way I've started the other 5. 2019 was a record year for DexCom. As CGM continues to drive therapy and the momentum grows, our business continues to perform beyond our expectations.
Let's talk a bit about the 2019 numbers. Revenue for 2019, for instance, can be approximately $1.47 billion. That's 42% over our 2018 numbers. In the fourth quarter, our estimated revenues were approximately $457 million,
DexCom Inc at JPMorgan Healthcare Conference Transcript
Jan 13, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers